Chi Advisors is an investment fund managing more than $329 billion ran by Ashley Latourelle. There are currently 25 companies in Mrs. Latourelle’s portfolio. The largest investments include Pliant Therapeutics and Acelyrin Inc, together worth $112 billion.
As of 4th August 2023, Chi Advisors’s top holding is 3,117,017 shares of Pliant Therapeutics currently worth over $56.5 billion and making up 17.1% of the portfolio value.
Relative to the number of outstanding shares of Pliant Therapeutics, Chi Advisors owns less than approximately 0.1% of the company.
In addition, the fund holds 2,663,806 shares of Acelyrin Inc worth $55.7 billion.
The third-largest holding is Vectivbio Hldg Ag worth $46.9 billion and the next is Cullinan Oncology worth $36.7 billion, with 3,414,189 shares owned.
Currently, Chi Advisors's portfolio is worth at least $329 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Chi Advisors office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Ashley Latourelle serves as the Chief Compliance Officer at Chi Advisors.
In the most recent 13F filing, Chi Advisors revealed that it had opened a new position in
Acelyrin Inc and bought 2,663,806 shares worth $55.7 billion.
The investment fund also strengthened its position in Pliant Therapeutics by buying
115,182 additional shares.
This makes their stake in Pliant Therapeutics total 3,117,017 shares worth $56.5 billion.
Pliant Therapeutics dropped 8.5% in the past year.
On the other hand, there are companies that Chi Advisors is getting rid of from its portfolio.
Chi Advisors closed its position in Prometheus Biosciences Inc on 11th August 2023.
It sold the previously owned 934,135 shares for $100 billion.
Ashley Latourelle also disclosed a decreased stake in Vectivbio Hldg Ag by 0.5%.
This leaves the value of the investment at $46.9 billion and 2,782,756 shares.
The two most similar investment funds to Chi Advisors are Ifrah Services and Redw Wealth. They manage $330 billion and $330 billion respectively.
Chi Advisors’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 50.9% of
the total portfolio value.
The fund focuses on investments in the United States as
40.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
24% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $324 million.
These positions were updated on August 11th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Prometheus Biosciences Inc |
Closed
934,135
|
$100,251,367,000 | |
| Pliant Therapeutics, Inc. |
3.84%
3,117,017
|
$56,480,348,000 | 17.15% |
| Acelyrin Inc |
Opened
2,663,806
|
$55,673,548,000 | 16.90% |
| Vectivbio Hldg Ag |
47.05%
2,782,756
|
$46,945,093,000 | 14.25% |
| Cullinan Oncology, LLC |
1.93%
3,414,189
|
$36,736,673,000 | 11.15% |
| Repare Therapeutics Inc. |
0.03%
2,998,734
|
$31,726,606,000 | 9.63% |
| Keros Therapeutics, Inc. |
54.03%
402,118
|
$16,157,101,000 | 4.90% |
| Ikena Oncology Inc |
27.77%
2,122,040
|
$13,920,582,000 | 4.23% |
| Compass Therapeutics Inc |
No change
2,829,712
|
$8,998,484,000 | 2.73% |
| Larimar Therapeutics, Inc. |
24.33%
3,414,468
|
$8,720,383,000 | 2.65% |
| 2seventy Bio Inc |
0.35%
852,007
|
$8,622,311,000 | 2.62% |
| Inozyme Pharma, Inc. |
10.96%
1,195,027
|
$6,656,301,000 | 2.02% |
| Omega Therapeutics Inc |
No change
1,055,882
|
$5,912,938,000 | 1.80% |
| Disc Medicine Inc |
Opened
125,139
|
$5,556,172,000 | 1.69% |
| Direxion Shs Etf Tr |
Opened
325,000
|
$4,670,250,000 | 1.42% |
| Orchard Therapeutics plc |
220.49%
2,518,181
|
$3,937,394,000 | 1.20% |
| Ultragenyx Pharmaceutical In |
Opened
85,000
|
$3,921,050,000 | 1.19% |
| Black Diamond Therapeutics I |
Opened
750,000
|
$3,787,500,000 | 1.15% |
| Chinook Therapeutics, Inc. |
Closed
135,000
|
$3,125,250,000 | |
| Rallybio Corp |
28.63%
542,774
|
$3,072,101,000 | 0.93% |
| Ovid Therapeutics Inc |
No change
864,822
|
$2,836,616,000 | 0.86% |
| Syros Pharmaceuticals Inc. |
No change
767,445
|
$2,417,452,000 | 0.73% |
| Kezar Life Sciences Inc |
Closed
689,451
|
$2,157,982,000 | |
| Freeline Therapeutics Hldgs |
Closed
4,729,419
|
$2,151,886,000 | |
| Precision BioSciences, Inc. |
53.79%
1,603,557
|
$843,471,000 | 0.26% |
| Entrada Therapeutics Inc |
Closed
56,374
|
$817,423,000 | |
| Oncorus, Inc. |
Closed
2,367,436
|
$814,634,000 | |
| Hookipa Pharma Inc |
Opened
788,740
|
$694,091,000 | 0.21% |
| Graphite Bio Inc |
Opened
230,938
|
$600,439,000 | 0.18% |
| Corvus Pharmaceuticals Inc |
91.45%
200,000
|
$458,000,000 | 0.14% |
| Freeline Therapeutics Hldgs |
Opened
25,999
|
$55,898,000 | 0.02% |
| No transactions found | |||
| Showing first 500 out of 31 holdings | |||